ADIM
IMCR icon

Alpha DNA Investment Management’s Immunocore IMCR Stock Holding History

Alpha DNA Investment Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,213
Closed -$411K – 222
2024
Q3 		$411K Buy
+13,213
New +$481K 0.15% 166

Other funds holding IMCR

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Alpha DNA Investment Management's IMCR Position: Q4 2024 in Review

Alpha DNA Investment Management sold out of Immunocore (IMCR) in Q4 2024, closing a stake of 13,213 shares — an estimated $411K sold.

Alpha DNA Investment Management first reported a position in IMCR in Q3 2024 and held it in 1 quarter. The position peaked at $411K in Q3 2024. 115 funds tracked by Wall St. Rank hold IMCR as of Q4 2024.

  • Alpha DNA Investment Management reported no remaining Immunocore position as of Q4 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 13,213 Immunocore shares in Q4 2024, an estimated $411K.
  • Alpha DNA Investment Management first reported a position in Immunocore in Q3 2024 and held it in 1 quarter.
  • Alpha DNA Investment Management's Immunocore position peaked at $411K in Q3 2024.
  • 115 funds tracked by Wall St. Rank held Immunocore as of Q4 2024.

Based on Alpha DNA Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.